Last updated: May 25, 2026
REMERON SOLTAB (mirtazapine) clinical trials update, market analysis and exclusivity-driven projection
Executive summary: REMERON SOLTAB is the mirtazapine orally disintegrating tablet (ODT) line of AbbVie’s REMERON brand (reference listed drug: mirtazapine). Commercially, ODT share is modest within the broader mirtazapine market, and the overall franchise is mature with limited incremental trial “pipeline” visibility tied to new chemical entity approvals. Near-term performance is driven primarily by brand-to-generic substitution, payers’ formulary positioning, and persisting demand for ODT dosing convenience in psychiatry. From a patent perspective, the practical risk for new entrants is generally IP light for mirtazapine itself, with any remaining exclusivity largely tied to specific formulations, dosing strengths, or Orange Book-listed patents.
No clinical-trials update, market sizing, or forward projection can be produced from the provided prompt alone because no sources (e.g., FDA communications, Orange Book patent listings, trial registries, company filings, or paid market datasets) are included in the input.
What is REMERON SOLTAB and how is it positioned vs generic mirtazapine?
Featured snippet answer: REMERON SOLTAB is mirtazapine ODT. It competes against generic mirtazapine tablets and generic ODTs where available, with ODT convenience as the primary differentiation.
Key product attributes that influence uptake
- Dosage form: orally disintegrating tablet (ODT)
- Active ingredient: mirtazapine (tetracyclic antidepressant)
- Therapeutic use: major depressive disorder (MDD), with off-label use in clinical practice depending on local approvals and evidence
Competitive substitution dynamics
- In most markets, generic mirtazapine compresses brand pricing.
- ODT formulations usually face slower switching than equivalent immediate-release tablets, but clinical equivalence under bioavailability standards typically still accelerates generic penetration after exclusivity expires.
What clinical trials are updating REMERON SOLTAB, mirtazapine ODT, or AB-rated equivalents?
Featured snippet answer: A true “clinical trials update” requires identifying ongoing, completed, or recruiting studies specifically tied to mirtazapine ODT or to the REMERON SOLTAB brand formulation.
Clinical-trials data needed for an accurate update
- Study identifiers (e.g., NCT numbers)
- Trial phase and endpoints (efficacy, safety, bioequivalence, patient-reported outcomes)
- Design type (switch studies, BE studies, comparative ODT vs tablet, adherence studies)
- Status dates and results availability
The prompt does not include trial registry links, NCT lists, or results documents; producing a specific update would require external inputs that are not present.
What is the market size for mirtazapine and how much of it is driven by ODT formulations?
Featured snippet answer: The relevant view is mirtazapine total prescriptions/sales, then the subset for ODT, then brand share vs generic share.
Market drivers for ODT within mirtazapine
- Adherence and swallowing preference: ODT can reduce barriers for patients with dysphagia
- Clinician and payer preferences: formularies sometimes steer toward least-cost generics unless ODT carries a meaningful access advantage
- Switching patterns: brand-to-generic substitution is often faster once equivalent products are widely distributed
What blocks accurate projection without datasets
- Baseline prescription volumes and unit sales by geography
- ODT vs tablet penetration by country
- Brand share and pricing, plus any wholesaler buying patterns
- Historical trends for at least 3 to 5 years
No market dataset or baseline numbers are provided in the prompt.
When does REMERON SOLTAB lose exclusivity and what patents protect mirtazapine ODT?
Featured snippet answer: For mirtazapine overall, the original compound is long out of primary patent coverage; any remaining exclusivity typically relates to specific Orange Book-listed patents covering formulation, manufacturing, or method-of-use for particular REMERON SOLTAB presentations.
Patent estate structure to evaluate (Orange Book framework)
- Drug substance patents (often expired)
- Drug product patents (formulation, ODT composition)
- Method-of-use patents (rare for legacy generics unless specifically granted)
- Manufacturing process patents (scale, granulation, lyophilization steps for ODT)
- Orphan exclusivity / pediatric / REMS effects (less common for this class)
Why a specific expiration map is impossible from the prompt
- A correct answer requires the exact Orange Book listing for REMERON SOLTAB (applicant, strength, dosage form)
- Patent numbers, listed expiration dates, and exclusivity codes
No Orange Book listing data is included.
What is the Orange Book status of REMERON SOLTAB and which ANDAs are approved or pending?
Featured snippet answer: The Orange Book status is a listing of approved applications, patent numbers, and whether other applicants hold Section viii carve-outs or have filed Paragraph IV certifications.
Items that must be enumerated for an actionable status
- ANDA AND applicant names (generic manufacturers)
- Approval dates for each ANDA
- Patent-by-patent certifications (e.g., Para III, Para IV)
- Litigation and whether settlements triggered “infringement carve-outs”
The prompt does not include the Orange Book record or ANDA list.
What Paragraph IV challenges exist for mirtazapine ODT, and what litigation affects generic entry?
Featured snippet answer: Paragraph IV litigation impacts generic launch timing only when it targets still-protected Orange Book patents.
What an accurate litigation review must include
- Court docket numbers and filings
- Asserted patents and certification statements
- Dates of complaints, motions, claim construction, and any settlement
- Settlement terms (180-day exclusivity, launch dates, carve-out scope)
No litigation references or dockets are provided.
How strong is the patent estate for REMERON SOLTAB vs competing mirtazapine products?
Featured snippet answer: Strength is determined by counting active Orange Book patents per strength and assessing remaining legal life plus enforceability against likely generic design-arounds.
Typical outcomes for mature mirtazapine products
- If only formulation patents remain, generics can often pursue design-around (different excipients, different disintegration profiles, alternative manufacturing).
- If remaining patents are weak or expired, the litigation tail is short.
Without Orange Book patent lists and claim details, strength cannot be quantified.
How does REMERON SOLTAB compare with other mirtazapine formulations (tablets, other ODTs) in patient outcomes and adoption?
Featured snippet answer: ODT offers dosing convenience versus conventional tablets, but clinical outcomes for depression largely track to mirtazapine pharmacology, with adherence and tolerability influenced by patient preference.
Competitive substitution factors
- Bioequivalence: drives pharmacy substitution
- Titration and side-effect management: mirtazapine’s known sedation and appetite effects affect early switching decisions
- Patient-reported ease of use: ODT can improve dosing reliability in some subgroups
No comparative study list is provided.
What generic entry risks exist for REMERON SOLTAB and which companies are best positioned?
Featured snippet answer: Generic entry risk depends on (1) remaining listed patents and (2) whether a generic ODT can be authorized without triggering Paragraph IV litigation.
Factors affecting “best positioned” generic entrants
- Litigation budget and ability to sustain Para IV actions
- Prior ODT development know-how (ODT formulation development, disintegration testing, stability)
- Supply chain readiness and distribution agreements
- Ability to secure 180-day exclusivity (if applicable)
No ANDA competitor list or patent status is provided.
Key Takeaways
- REMERON SOLTAB is mirtazapine ODT, competing in a mature antidepressant market where generic substitution dominates.
- A defensible clinical trials update requires specific trial registry data (NCTs, statuses, endpoints) tied to mirtazapine ODT.
- A defensible market analysis and projection requires baseline units, pricing, formulary/market share by ODT vs tablet, and geography.
- A defensible exclusivity and patent timeline requires the exact Orange Book record for REMERON SOLTAB strengths and dosage form, including listed patent numbers and expiration dates.
FAQs
- Which FDA application pathways apply to generic mirtazapine ODT versus REMERON SOLTAB?
- Are there bioequivalence or formulation considerations unique to mirtazapine ODT that affect generic approvals?
- What is the typical payor behavior for legacy antidepressant brands after generic ODT entry?
- How do settlement terms in Paragraph IV cases usually affect launch timing for ODT competitors?
- What patient subgroups are most likely to prefer ODT over standard mirtazapine tablets?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via web tool not provided in prompt.)
- ClinicalTrials.gov. Search results not provided in prompt.
